BioCentury | Jun 10, 2020
Emerging Company Profile

Autobahn: fine-tuning thyroid agonism to remyelinate axons

Autobahn, which launched with a $76 million series B Tuesday, joins at least six other companies with disclosed remyelination programs for multiple sclerosis. But the biotech thinks its prodrug, slated to enter the clinic next...
BC Extra | Jul 20, 2017
Financial News

NeuroVia raises $14M in series A

Rare disease company NeuroVia Inc. (San Francisco, Calif.) raised $14 million in a series A round led by Novartis Venture Fund (NVF) and Sanofi-Genzyme BioVentures (SGBV). Also participating were BioMed Ventures and Enso Ventures. Founder...
BC Innovations | Oct 20, 2016
Translation in Brief

Viking’s heart bypass

Viking Therapeutics Inc. (NASDAQ:VKTX) has presented data showing its preclinical thyroid hormone receptor β agonist, VK0214 , cut down pathogenic accumulation of very long chain fatty acids (VLCFAs) in a mouse model of X-linked adrenoleukodystrophy (X-ALD)....
Items per page:
1 - 3 of 3